Advances in the radiation retinopathy
10.3980/j.issn.1672-5123.2025.8.12
- VernacularTitle:放射性视网膜病变的研究进展
- Author:
Jingjing ZUO
1
;
Li ZHANG
1
;
Taiguo LIU
1
Author Information
1. Department of Radiotherapy, Chengdu Seventh People's Hospital（Affiliated Cancer Hospital of Chengdu Medical College）, Chengdu 610213, Sichuan Province, China
- Publication Type:Journal Article
- Keywords:
radiation retinopathy;
radiation maculopathy;
pathogenesis;
anti-vascular endothelial growth factor therapy
- From:
International Eye Science
2025;25(8):1280-1284
- CountryChina
- Language:Chinese
-
Abstract:
Radiation retinopathy(RR)is a chronic and progressive retinal vascular disease that occurs during radiotherapy for tumors. It is commonly seen after radiotherapy for head and neck tumors, especially those close to the eye. The incidence and severity of RR are influenced by risk factors such as radiation location, radiation type, and radiation dose. The basic pathological change of RR is the damage to vascular endothelial cells which could lead to maculopathy and subsequent vision loss. The interventions for RR include prophylaxis and treatment. Prophylaxis has been proved effective for reducing the occurrence of RR. Intravitreal injection of anti-vascular endothelial growth factor(VEGF)agents was the first-line therapy for treating RR, and corticosteroids and laser photocoagulation could serve as supplements. This article reviewed the risk factors, pathogenesis, clinical manifestations, and diagnostic and treatment methods of RR, aiming to enhance the understanding of RR and summarize the recent advances in RR.
